Thomas Jensen
Chief Executive Officer, Founder
Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, and a director since July 2022. He has been a part of the company since its inception, serving in various capacities. Mr. Jensen is also the CEO of TEQCool AB, a private technology company. Before becoming the CEO, Mr. Jensen served as Senior Vice President, Investor Relations since June 2022. Previously, he served as Senior Vice President of Information Technology of Allarity Therapeutics, Inc. and its predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen also served as the Chief Technology Officer of the predecessor from 2004 to June 2020.

Mr. Jensen co-founded Allarity Therapeutics A/S in 2004 and established and currently leads the company's laboratories in Denmark. He is instrumental in building investor relations, securing financing, and fostering business growth. Mr. Jensen's innovations in molecular biological guidelines and techniques for high-quality reproducible RNA extraction and downstream processing have significantly contributed to the company's success.

Mr. Jensen's inventions are a foundational part of the DRP® - Drug Response Prediction platform. He also serves on the Board of Cardeon AB, a Swedish company investing in innovative Nordic companies and start-ups in technology and life sciences. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark and conducted further studies in Biology at the University of Copenhagen.

Joan Y. Brown
Chief Financial Officer
Ms. Brown has served as CFO (interim) since June 2022. Previously, she was the Company's Director of Financial Reporting, a position she has held since 2021, where she assisted in the Company's move to the U.S. Nasdaq. She brings over 20 years of experience in financial and regulatory reporting, audit, full-cycle accounting, payroll, and management.

Prior to joining Allarity, Ms. Brown served as a consultant to various public and private companies, providing financial reporting and regulatory compliance services. She also served as Director of Prudential Supervision at the Financial Institutions Commission (FICOM) in Vancouver, BC, Canada. Ms. Brown is a Certified Public Accountant (CPA), a Chartered Accountant (Canada), and holds a bachelor’s degree in Business Administration from Simon Fraser University.

Steen Knudsen
Chief Scientific Officer, Founder
Steen Knudsen has been the Chief Scientific Officer of the predecessor since 2006 and continues in this role. Dr. Knudsen is a co-founder of Allarity Therapeutics A/S and the inventor of the DRP® platform, the core technology of the company.

Dr. Knudsen is a former Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. He co-founded the predecessor in 2004 and served as its CEO from 2004 to 2006. Dr. Knudsen also served as a member of the predecessor's Board of Directors from 2016 to 2020. He currently serves as the Chief Executive Officer of MPI, Inc., the company's operating subsidiary in the U.S.

Dr. Knudsen holds an M.Sc. degree in Engineering from the Technical University of Denmark and a Ph.D. degree in Microbiology from the University of Copenhagen. He received postdoctoral training in computational biology from Harvard Medical School.

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.

Allarity Therapeutics, Inc.  (the “Company”) has reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.

Information and opinions presented in the Company Presentation are provided by the Company, and b2iDigital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment. 

Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.

A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.

Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.

b2i digital or its related entities may own securities of the Company.

The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.

This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.